Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00568334
Other study ID # 109705
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 1, 2007
Est. completion date April 29, 2008

Study information

Verified date April 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.


Recruitment information / eligibility

Status Completed
Enrollment 244
Est. completion date April 29, 2008
Est. primary completion date March 18, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Months to 21 Months
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.

- A male or female between, and including, 11 and 21 months of age at the time of the first vaccination.

- Written informed consent obtained from the parent or guardian of the subject.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

- Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days prior to the first study vaccine dose until 42 days after second study vaccine dose with the exception of oral polio vaccine (OPV) which can be given at any time and routine inactivated vaccines which can be administered up to eight days before each study vaccine dose.

- Previous vaccination against varicella.

- Known history of clinical varicella.

- Known exposure to varicella within 30 days prior to study start.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

- A family history of congenital or hereditary immunodeficiency.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic hypersensitivity to neomycin.

- Major congenital defects or serious chronic illness.

- Acute disease at the time of enrolment. All vaccines can be administered to persons with a minor illness.

- Axillary temperature = 37.5°C / Rectal temperature = 38°C.

- Residence in the same household as a high risk person e.g.: new-born infants (0-4 weeks of age), pregnant women who have a negative history of chickenpox, persons with known immunodeficiency

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Varilrix (inactivated varicella vaccine)
subcutaneously injection

Locations

Country Name City State
Czechia GSK Investigational Site Nachod
Czechia GSK Investigational Site Pardubice
Hungary GSK Investigational Site Bordány
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Gyor
Hungary GSK Investigational Site Miskolc
Hungary GSK Investigational Site Miskolc
Hungary GSK Investigational Site Miskolc
Hungary GSK Investigational Site Szeged
Hungary GSK Investigational Site Zsombó

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Czechia,  Hungary, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibody Titers Against Varicella Zoster Virus (VZV) Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects [with anti-VZV titer below (<) 1:4]. At 43-57 days after the first vaccine dose (Week 6)
Primary Antibody Concentrations Against Varicella Zoster Virus (VZV) Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects [with anti-VZV concentration below (<) 25 mIU/mL]. At 43-57 days after the first vaccine dose (Week 6)
Secondary Number of Seroconverted Subjects for Varicella Antibodies Seroconversion/seroresponse (considering the IFA data) was defined as the appearance of anti-VZV antibodies [i.e. titer/concentration greater than or equal to (=) the assay cut-off value of 1:4] in the sera of subjects who were seronegative before vaccination. At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Secondary Number of Subjects With Anti-VZV Antibody Concentrations Above Cut-off Values Anti-VZV antibody concentrations greater than or equal to (=) the assay cut-off values of: 25 mIU/mL, 50 mIU/mL and 75 mIU/mL have been assesssed by ELISA, in the sera of subjects who were seronegative before vaccination. At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Secondary Antibody Titers Against Varicella Zoster Virus (VZV) Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects [with anti-VZV titer below (<) 1:4]. At 86-114 days after the second vaccine dose (Week 12)
Secondary Antibody Concentrations Against Varicella Zoster Virus (VZV) Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects [with anti-VZV concentration below (<) 25 mIU/mL]. At 86-114 days after the second vaccine dose (Week 12)
Secondary Number of Subjects With Any and Grade 3 Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site. During the 4-day (Days 0-3) post-vaccination period following each dose
Secondary Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Assessed solicited general symptoms were fever [defined as axillary fever = 37.5 degrees Celsius (°C)] and generalized rash. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 fever = temperature above (>) 39.0°C after vaccination. Grade 3 rash = more than (>) 150 lesions. Related = considered by the investigator to be causally related to the study vaccination. During the 43-day (Days 0-42) post-vaccination period following each dose
Secondary Number of Subjects With Any Unsolicited Adverse Event (AE) An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Within the 43-day (Days 0-42) post-vaccination period following each dose
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. From Day 0 up to study end (Day 86-114)
See also
  Status Clinical Trial Phase
Completed NCT00792623 - Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). Phase 2
Enrolling by invitation NCT05015686 - Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00226499 - Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Not yet recruiting NCT06068608 - A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy Phase 1
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT00715234 - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients N/A
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT03239873 - Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT01390857 - Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) N/A
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00578175 - Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Phase 2
Completed NCT03114982 - The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age Phase 2
Completed NCT00483574 - Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Phase 3
Completed NCT00127023 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3